United States
Print page content Print
Increase text size Decrease text size
Text Size

In this section

Efficacy

PALLADIA has demonstrated single agent efficacy against MCTs in a clinical field efficacy study.

  •    PALLADIA is a novel oral therapy that has been specifically developed for dogs
    •    Blocks the activity of multiple receptors, providing antiangiogenic3
           and antiproliferative effects
  •    Clinical field study with single-agent PALLADIA therapy3
    •    Multicenter, placebo-controlled, double-blind, randomized study (N=151)
    •    37.2% objective response rate in dogs (during 6-week blinded phase)
    •    Approximately 60% of toceranib phosphate-treated dogs achieved a
           biological response during the blinded plus the open-label phase
      •    42.8% objective response rate for all toceranib phosphate–treated dogs
             in blinded plus open-label phase
  •    Equivalent or higher objective response rates when compared with previous3,4,5,6,7,8,9
              single-agent lomustine/vinblastine studies in dogs with gross disease

IMPORTANT SAFETY INFORMATION: During clinical studies, the most common adverse events associated with PALLADIA included: diarrhea, anorexia (including decreased appetite), lethargy, neutropenia, emesis, lameness, weight loss, musculoskeletal disorder, and blood in stool/GI bleed/hemorrhagic diarrhea. PALLADIA may cause vascular dysfunction, which can lead to edema and thromboembolism, including pulmonary thromboembolism. Serious and sometime fatal GI complications, including GI perforation, have occurred rarely in dogs treated with PALLADIA. If GI ulceration is suspected stop drug administration and treat appropriately. Children should not come in contact with PALLADIA. In addition, all individuals, including children and pregnant women, should avoid direct contact with broken or partially dissolved PALLADIA tablets or biological waste from dogs treated with PALLADIA. To report a suspected adverse reaction call Zoetis at 1-888-963-8471. See full Prescribing Information

All trademarks are the property of Zoetis Inc., its affiliates and/or its licensors. Zoetis Inc. All rights reserved. August 2015. PAL-00040

REFERENCES:

3. London CA, Malpas PB, Wood-Follis SL, et al. Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 2009, 151(11):3856-3865.
4. Hahn KA, Ogilvie G, Rusk T, et al. Masitinib is safe and effective for the treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1301-9.
5. Rassnick KM, Bailey DB, Flory AB, et al. Efficacy of vinblastine for treatment of canine mast cell tumors. J Vet Intern Med 2008;22:1390-6.
6. Grant IA, Rodriguez CO, Kent MS, et al. A phase II clinical trial of vinorelbine in dogs with cutaneous mast cell tumors. J Vet Intern Med 2008;22:388-93.
7. Rassnick KM, Moore AS, Williams LE, et al. Treatment of canine mast cell tumors with CCNU (lomustine). J Vet Intern Med 1999;13:601-5.
8. McCaw DL, Miller MA, Bergman PG, et al. Vincristine therapy for mast cell tumors in dogs. J Vet Intern Med 1997;11:375-8.
9. McCaw DL, Miller MA, Ogilvie GK, et al. Response of canine mast cell tumors to treatment with oral prednisone. J Vet Internal Med 1994;8:406-8